The company was founded in 1998 and is an enterprise focusing on liver disease treatment. The subsidiaries are located in France, Spain, Germany, the United States, Hong Kong and other major provincial capitals. The company was listed on the Shenzhen Stock Exchange GEM in 2010. The company's main business is pharmaceutical production and sales, research and development and sales of diagnostic equipment, and medical services. The company's main products: compound turtle liver tablets, FibroScan series liver fibrosis diagnostic instruments, managed medical strategies, pediatric healthcare management. Corporate honors: “2019 Corporate Social Responsibility Industry Model Award” at the 9th China Charity Festival, “2020 Charity Group Award Project Award” at the 10th China Charity Festival, “Companies Listed on the IR Interactive Activity List” for A-share listed companies in 2018, etc.